MTD Group takes part in the global effort to accelerate the COVID-19 vaccination, thanks to its new Low Dead Space syringes
PR89776
LUGANO, Switzerland, May 28, 2021 /PRNewswire=KYODO JBN/ --
In delivering the COVID-19 global vaccination campaign, it is of paramount
importance to be able to maximize the number of individuals that can benefit
from the available vaccine vials.
In particular, the use of low dead space (LDS) syringes can enable HCPs to
extract more doses than those originally foreseen for each vial.
As an example, Pfizer indicates how to extract 6 doses from a single vial of
their COVID-19 vaccine, therefore minimizing vaccine waste. In order to do
that, low dead space syringe and needle combination should have a dead-space of
no more than 35 microlitres (0.035 mL).
Similarly, Moderna has recently received approval from the US Food and Drug
Administration (FDA) for distributing 2 different vials, containing up to 11
and up to 15 doses of their COVID-19 vaccine, respectively. However, proper
syringes with reduced dead space are needed to extract all the 11 (respectively
15) doses from each vial.
The MTD Group, leveraging its Research Hub located in Como (Italy), with its
decades of experience in designing and producing needles and syringes, has made
investments to take part in the global effort to supply products that will
minimize vaccine waste, and help to accelerate the COVID-19 vaccination effort
according to the above recommendations.
As a result, we are ready to offer improved syringes (with and without needles,
in order to guarantee flexibility of use) with a total dead space below 35
microlitres.
Pfizer has conducted preliminary tests on our newly developed products, in
order to validate the above specification, with positive results. Please refer
to: https://www.comirnatyeducation.ie/files/LDV-Sheet_V6.pdf
In particular, we are ready to start supplying the following solutions:
Low Dead Space (LDS) syringe with a luer slip, to be coupled with 23Gx1" or
25Gx1" needles
Syringe type
- PIC Solution 1ml LDS syringe - Luer Slip (MTD Group) ref.
02071000090540/02071000090180
Needle type
- PIC Solution Hypodermic Needle 23G x 1" (MTD Group) ref.
02070160300800/02081230250150
- PIC Solution Hypodermic Needle 25G x 1" (MTD Group) ref.
02070255300800/02081250250150
Low Dead Space (LDS) syringe with an integrate 25Gx1" needle (available end-Q3)
- PIC Solution 1ml LDS syringe w/ fixed needle 25G x 1" (MTD Group) ref.
02071300250150
To know the available options for your specific needs or to have more
information: covidportfolio@mtdglobal.com.
Logo - https://mma.prnewswire.com/media/1519260/MTD_Group_Logo.jpg
Source: MTD Group
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。